Study to Evaluate the Ability of Sublingual MV130 to Induce the Expression of Trained Immunity in Peripheral Blood Cells

NCT05208060 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Immune Response

Interventions

BIOLOGICAL: MV130
OTHER: Placebo

Sponsor

Inmunotek S.L.